Novo Nordisk partnered with Vivtex in a deal worth up to $2.1 billion to develop oral medicines for obesity and diabetes. Vivtex will license its drug delivery technology, allowing injectable biologics to be taken orally. Novo will lead development and commercialisation, aiming to transform treatment options for metabolic conditions.